Recombinant human leukemia inhibitory factor does not improve implantation and pregnancy outcomes after assisted reproductive techniques in women with recurrent unexplained implantation failure

被引：59

作者：

Brinsden, Peter R. ^{[1
]}

Alam, Veronica ^{[2
]}

de Moustier, Beatrice ^{[2
]}

Engrand, Patrick ^{[2
]}

机构：

[1] Bourn Hall Clin, ACU, Cambridge CB23 2TN, England

[2] Merck Serono Int SA, Geneva, Switzerland

来源：

FERTILITY AND STERILITY | 2009年 / 91卷 / 04期

关键词：

FACTOR LIF; EMBRYO IMPLANTATION; HUMAN ENDOMETRIUM; CELLS;

D O I：

10.1016/j.fertnstert.2008.06.047

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

In this randomized, double-blind, placebo-controlled, multicenter study, women (n = 149) with a history of at least two unexplained implantation failures after assisted reproductive techniques received recombinant human leukemia inhibitory factor, 150 mu g SC twice daily for 7 days, or placebo. The clinical pregnancy rate after ET was significantly lower in patients receiving recombinant human leukemia inhibitory factor than in those receiving placebo (17.6% vs. 34.0%, respectively). (Fertil Steril (R) 2009;91:1445-7. (C) 2009 by American Society for Reproductive Medicine.)

引用

页码：1445 / 1447

页数：3

共 12 条

[1] Use of recombinant leukemia inhibitory factor in embryo implantation [J].